Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Many US COVID-19 Guidances Set To Sunset With Emergency Declaration

Executive Summary

But some, including some related to inspections and master protocols, will remain in effect to allow for revisions or a transition out of the pandemic posture.

You may also be interested in...



US FDA Removes Minimum Efficacy Bar For COVID-19 Vaccines

Instead of the 50% threshold, the FDA in updated guidance says that efficacy confidence intervals and point estimates should be ‘appropriately justified.’

US FDA Program Streamlining COVID-19 Treatment Development Still Working As Emergency Ends

Any program changes would not occur until after a thorough assessment, the agency said.

US FDA ‘Brainstorms’ For Ways To Resume Pre-Pandemic Inspection Cadence

The FDA's drug inspections director discusses trends and challenges in remarks at a Georgia GMP conference, while declining to share specific ideas generated in last week’s agency brainstorming session.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel